Q2 FY2026 · ended Jun 30, 2026 · Revenue $114.44M, +11.4% YoY · Filed Aug 3, 2026
GeneDx Holdings Corp. (WGS) files with the SEC under industry code 8000, Services-Health Services. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $114.4 million and a net loss of $17.7 million. Free cash flow was -$39.1 million. As of Jun 30, 2026 it held $132.5 million in cash and investments and $100.0 million in total debt.
Revenue
$114.44M
+11.4% vs year-ago quarter
Net income
$-17.74M
-264.1% vs year-ago quarter
Operating cash flow
$-28.98M
-378.1% vs year-ago quarter
Free cash flow
$-39.09M
-585.6% vs year-ago quarter
EPS
$-0.60
-266.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
29.82M
+3.8% vs year-ago quarter
Net cash
$32.55M
Q2 FY2026
Operating margin
-20.3%
TTM
Company profile
- Industry
- Services-Health Services (SIC 8000)
- Listed as
- WGS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Stamford, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1818331
- Former names
- Sema4 Holdings Corp. (until Jan 5, 2023); CM Life Sciences, Inc. (until Jul 21, 2021)
Other Services-Health Services companies
- LifeStance Health Group, Inc. LFST
- Privia Health Group, Inc. PRVA
- Pennant Group, Inc. PNTG
- U S Physical Therapy Inc /NV USPH
- InnovAge Holding Corp. INNV
- Omada Health, Inc. OMDA
- P3 Health Partners Inc. PIII
- Alps Group Inc ALPS
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $114.4M | $102.3M | $121.0M | $116.7M | $102.7M |
| Operating income | -$17.5M | -$57.5M | -$14.2M | -$3.3M | $9.0M |
| Net income | -$17.7M | -$63.3M | -$17.7M | -$7.6M | $10.8M |
| Diluted EPS | -$0.60 | -$2.16 | -$0.61 | -$0.27 | $0.36 |
| Operating cash flow | -$29.0M | -$32.4M | -$3.1M | $15.8M | $10.4M |
| Free cash flow | -$39.1M | -$38.9M | -$7.4M | $9.6M | $8.1M |
| Total assets | $481.5M | $506.3M | $523.7M | $493.9M | $463.9M |
| Total liabilities | $237.3M | $252.2M | $215.5M | $201.6M | $186.7M |
| Stockholders' equity | $244.2M | $254.1M | $308.2M | $292.3M | $277.1M |
| Cash and investments | $132.5M | $170.7M | $171.3M | $155.1M | $134.6M |
| Total debt | $100.0M | $100.0M | $115.0M | $54.8M | $55.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 16, 2026 | Jun 15, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 4, 2026 | May 4, 2026 |
All 781 GeneDx Holdings Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.